DOCSLIB.ORG

Cell-Intrinsic Manner Phenotype CD8 T Cell Subsets in a Programmed Death-1 Shapes Memory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cell-Intrinsic Manner Phenotype CD8 T Cell Subsets in a Programmed Death-1 Shapes Memory Programmed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner This information is current as Joanna J. Charlton, Ioannis Chatzidakis, Debbie Tsoukatou, of September 29, 2021. Dimitrios T. Boumpas, George A. Garinis and Clio Mamalaki J Immunol 2013; 190:6104-6114; Prepublished online 17 May 2013; doi: 10.4049/jimmunol.1201617 Downloaded from http://www.jimmunol.org/content/190/12/6104 Supplementary http://www.jimmunol.org/content/suppl/2013/05/17/jimmunol.120161 Material 7.DC1 http://www.jimmunol.org/ References This article cites 60 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/190/12/6104.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Programmed Death-1 Shapes Memory Phenotype CD8 T Cell Subsets in a Cell-Intrinsic Manner Joanna J. Charlton,*,†,1 Ioannis Chatzidakis,*,‡,1 Debbie Tsoukatou,* Dimitrios T. Boumpas,*,† George A. Garinis,*,‡ and Clio Mamalaki* Memory phenotype T cells, found in unimmunized mice, display phenotypic and functional traits of memory cells and provide essential protection against infections, playing a role in both innate and adaptive immune responses. Mechanisms governing ho- meostasis of these memory phenotype T cells remain ill-defined. In this study, we reveal a crucial role of the negative costimulator programmed death-1 (PD-1) in regulating developmental fates of memory phenotype cells. Thus, in lymphoid organs and tissues of PD-1 knockout (KO) mice a marked accumulation of functional effector memory (TEM) phenotype CD8 T cells was observed. TEM phenotype cells from PD-1 KO mice exhibit decreased proliferation but increased survival potential. These cells could produce effector molecules constitutively, in response to phorbol esters or through bystander activation by innate stimuli. Similarly, in Downloaded from lymphopenia-induced proliferating CD8 T cells, whereby normally naive T cells acquire a memory phenotype, skewing toward aTEM phenotype was prominent in the absence of PD-1. Acquisition of the TEM phenotype was a CD8 T cell–intrinsic phenom- enon as demonstrated by mixed bone marrow transfer experiments. Importantly, adoptively transferred PD-1 KO CD8 central memory T (TCM) cells converted into the TEM phenotype, indicating that PD-1 sets a major checkpoint in the TCM to TEM phenotype differentiation process. This was reflected by distinct patterns of gene expression of PD-1 KO TCM phenotype cells http://www.jimmunol.org/ revealed by global transcriptional analysis. Additionally, adoptively transferred PD-1 KO TEM phenotype cells converted to alesserdegreetoaTCM phenotype. Collectively, these data suggest that PD-1 shapes memory phenotype CD8 T cell sub- sets. The Journal of Immunology, 2013, 190: 6104–6114. emory phenotype (MP) T cells are found in normal, pathogens during a primary response mostly by producing IFN-g unimmunized mice and display phenotypic and func- (bystander activation) in response to IL-12, IL-18, and IFN-a/b M tional traits of memory cells; they account for 10–20% produced by macrophages and dendritic cells (3, 4). MP and Ag- of T cells in young mice, and their number increases with age. It specific memory CD8 T cells can be broadly divided into central is thought that they are generated as a result of lifetime exposure memory (TCM) and effector memory (TEM) cells based on dif- by guest on September 29, 2021 to various environmental Ags, self-Ags (1), or even simply by ho- ferential expression of CCR7 and CD62L and different properties meostatic expansion mechanisms. Signaling by IL-7 and/or other regarding effector functions, migration to lymphoid organs or common g-chain cytokines, such as IL-15, can induce naive T tissues, as well as proliferation in response to Ag or cytokines (5). hi hi hi cells to undergo homeostatic proliferation and convert into cells TCM cells are CD44 CD62L CCR7 and migrate preferentially hi lo lo with a memory phenotype (2). Apart from their role in secondary to lymph nodes, whereas TEM cells are CD44 CD62L CCR7 adaptive immune responses, MP cells seem to display important and are mostly located in spleen, peripheral tissues, and bone innate immune responses that provide early protection against marrow. TEM cells provide immediate effector functions at the site of pathogen entry through production of lytic molecules such as perforin and granzymes as well as IFN-g (5–8). *Institute of Molecular Biology and Biotechnology, Foundation for Research and Several models have been proposed to explain the lineage Technology–Hellas, GR-70013 Heraklion, Crete, Greece; †School of Medicine, Uni- versity of Crete, GR-71003 Heraklion, Crete, Greece; and ‡Department of Biology, relationship of TEM and TCM Ag-specific memory subsets. The University of Crete, GR-71003 Heraklion, Crete, Greece question of memory subset interconversion has been addressed in 1 J.J.C. and I.C. contributed equally to this work. different experimental systems, and both conversion of TEM to Received for publication June 12, 2012. Accepted for publication April 12, 2013. TCM cells (9, 10) and TCM to TEM cells have been reported (11– This work was supported by the “Synergasia” program of the Greek General Secre- 13). Importantly, recent studies have shown that a single naive tariat for Research and Technology (Grant 09SYN-12-1074) and by the European precursor cell is able to give rise to all different memory subsets Commission research program Inflammation and Cancer Research in Europe (Con- tract 223151). (14, 15). Although mechanisms governing subset differentiation The microarray data presented in this article have been submitted to ArrayExpress of memory T cells is the subject of intense investigation, homeo- (http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-1569. stasis of MP T cell subsets is less well studied. Address correspondence and reprint requests to Dr. Clio Mamalaki, Institute of Costimulation has been shown to be a critical parameter in de- Molecular Biology and Biotechnology, Foundation for Research and Technology– termining the developmental fate of memory T cells (16–22). Pro- Hellas, Nikolaou Plastira 100, GR-70013 Heraklion, Crete, Greece. E-mail address: [email protected] grammed death-1 (PD-1) is an immunoreceptor that belongs to The online version of this article contains supplemental material. the CD28/CTLA-4 family and is expressed (among others) on activated CD4 and CD8 T cells. PD-1 negatively regulates TCR Abbreviations used in this article: GzmB, granzyme B; KO, knockout; LIP, lympho- penia-induced proliferation; MP, memory phenotype; PD-1, programmed death-1; signaling upon engagement of one of its ligands PD-ligand 1 and SNARF-1, seminaphtorhodafluor-1-carboxylic acid acetate succinimidyl ester; SP, PD-ligand 2 (23, 24). Apart from the established role of PD-1 in single-positive; T , central memory T; T , effector memory T; WT, wild-type. CM EM peripheral T cell tolerance, its role in immunity and infection is Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00 also well described. PD-1 is highly expressed on virus-specific www.jimmunol.org/cgi/doi/10.4049/jimmunol.1201617 The Journal of Immunology 6105 CD8 T cells in chronic infections and is correlated with an with RPMI 1640 by centrifugation at 800 3 g for 5 min at 4˚C. Subsequent “exhausted” T cell phenotype that is reversed upon PD-1 neu- removal of RBCs was performed by water lysis. tralization (25, 26). The PD-1 pathway can compromise CD8 In vivo or in vitro stimulation and intracellular cytokine T cell responses during some acute infections and contributes staining to the functional impairment of “helpless” CD8 T cells (27). The role of PD-1 in generation, maintenance, and function of MP CD8 For cytokine production, splenocytes were incubated for 4 h in the presence of GolgiPlug (BD Biosciences) and 50 ng/ml PMA and 500 ng/ml ion- T cells is less clear. MP CD8 T cells express PD-1, especially in omycin (both from Sigma-Aldrich) or untreated. For all experiments culture aged mice, but to a lesser extent compared with MP CD4 T cells medium was RPMI 1640 (Biosera) supplemented with 10% FBS, 10 mM (28), and most PD-1–expressing MP CD8 T cells belong to the HEPES, 100 U/ml penicillin-streptomycin, 2 mM L-glutamine, and 50 mM + 2-ME. In some experiments 3-mo-old WT and PD-1 KO mice were TEM phenotype. Interestingly, PD-1 expression on MP CD8 + challenged with 50 mgLPS(Escherichia coli 0111:B4) (Sigma-Aldrich) CD122 T cells defines an IL-10–producing regulatory T cell or PBS for 4 h and were then sacrificed and splenocyte suspensions were + population (29). In settings of lymphopenia, a short-lived PD-1 incubated with GolgiPlug. Cells were washed and stained for surface fraction has been identified among homeostatically proliferating markers, as previously described. Cells were then fixed and rendered (lymphopenia-induced proliferating, LIP) CD8 T cells, charac- permeable by using a Cytofix/Cytoperm kit (BD Biosciences), according to terized by poor functional responses (30).
Load more

Recommended publications
  • T Cells the Usual Subsets
    T cells: the usual subsets Chen Dong and Gustavo J. Martinez T cells have important roles in immune responses and function by directly secreting soluble mediators or important for adaptation of immune responses in different microenvironments and might be particularly through cell contact-dependent mechanisms. Many T cell subsets have been characterized. Although relevant for host defence against pathogens that colonize different tissues. Distinct T cell subsets, or effector T cells were originally considered to be terminally differentiated, a growing body of evidence has differentiation states, can be identified based on the cell surface markers expressed and/or the effector challenged this view and suggested that the phenotype of effector T cells is not completely fixed but is molecules produced by a particular T cell population. This Poster summarizes our current understanding of more flexible or plastic. T cells can have ‘mixed’ phenotypes (that is, have characteristics usually the surface markers, transcriptional regulators, effector molecules and functions of the different T cell associated with more than one T cell subset) and can interconvert from one subset phenotype to another, subsets that participate in immune responses. Further knowledge of how these T cell subsets are regulated IMMUNOLOGY although instructive signalling can lead to long-term fixation of cytokine memory. T cell plasticity can be and cooperate with each other will provide us with better tools to treat immune-related diseases. Cytotoxic T cell Exhausted T cell
    [Show full text]
  • T Lymphocytes + and CD8 +CD4 TCR/CD3 Complex in Immortalized Mature -Deficient Γ Signaling Through A
    Signaling Through a CD3γ-Deficient TCR/CD3 Complex in Immortalized Mature CD4+ and CD8+ T Lymphocytes This information is current as Alberto Pacheco-Castro, David Alvarez-Zapata, Pilar of September 25, 2021. Serrano-Torres and José R. Regueiro J Immunol 1998; 161:3152-3160; ; http://www.jimmunol.org/content/161/6/3152 Downloaded from References This article cites 47 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/161/6/3152.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Signaling Through a CD3g-Deficient TCR/CD3 Complex in Immortalized Mature CD41 and CD81 T Lymphocytes1 Alberto Pacheco-Castro,2 David Alvarez-Zapata,2 Pilar Serrano-Torres, and Jose´R. Regueiro3 The biologic role of each CD3 chain and their relative contribution to the signals transduced through the TCR/CD3 complex and to downstream activation events are still controversial: they may be specialized or redundant.
    [Show full text]
  • 18F-Farag PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy
    Journal of Nuclear Medicine, published on November 6, 2020 as doi:10.2967/jnumed.120.249078 18F-FAraG PET for CD8 Profiling of Tumors and Assessment of Immunomodulation by Chemotherapy Jelena Levi1*, Samuel Goth1, Lyna Huynh1, Tina Lam1, Tony L Huynh2, Brailee Schulte2, Juliet A Packiasamy1 1CellSight Technologies Incorporated, San Francisco, California; 2Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; *Corresponding Author Jelena Levi, PhD 185 Berry street, San Francisco, 94107, CA Email: [email protected] Running Title: [18F]F-AraG for CD8 profiling of tumors Financial statement: This work was supported by National Institutes of Health Grants NCI SBIR HHSN261201800024C (JL). Conflict of Interest Statement: JL, SG, LH, TL and JP are or were employed by CellSight Technologies. CellSight Technologies Incorporated is commercializing [18F]F-AraG as a PET tracer for evaluation of immune response in immunotherapy. No other potential conflicts of interest relevant to this article exist. ABSTRACT Majority of the clinical trials exploring various combinations of chemo- and immunotherapy rely on serial biopsy to provide information on immune response. The aim of this study was to assess the value of 18F-FAraG as a non-invasive tool that could profile tumors based on the key players in adaptive antitumor response, CD8+ cells, and evaluate immunomodulatory effects of chemotherapy. Methods. To evaluate the ability of 18F-FAraG to report on the presence of CD8+ cells within the TME, we imaged a panel of syngeneic tumor models (MC38, CT26, LLC, A9F1, 4T1 and B16F10), and correlated the signal intensity with the number of lymphocytes found in the tumors.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Identification of 18 Immune Cell Subsets Using 13-Color Panel
    Immunophenotyping Identification of 18 immune cell subsets in human blood using a 13-color panel Background Cell type Function Phenotype Flow cytometry has become the method of choice for Eosinophils Parasitic immunity CD45+, SSCmid/hi, CD14 –, CD16 –, CD19– immunophenotyping and identifying specific cellular + mid/hi subsets. Within seconds, it provides a thorough overview of Neutrophils Innate Immunity CD45 , SSC , CD14 –, CD16+, CD19– the major cell types that constitute a sample. Using multiple + mid markers simultaneously increases the number of parameters Classical Phagocytosis of CD45 , SSC , monocytes pathogens and CD14+, CD16– that can be analyzed per run and decreases the amount of antigen presentation starting material required to perform an assay. This can be Intermediate Phagocytosis of CD45+, SSCmid, critical for precious sample material and long-term immune- monocytes pathogens and CD14+, CD16mid monitoring studies. In this application note, we demonstrate antigen presentation 13-color immunophenotyping of human peripheral blood Non-classical Phagocytosis of CD45+, SSCmid, + + mononuclear cells (PBMCs) using the MACSQuant® Analyzer 16, monocytes pathogens and CD14 , CD16 antigen presentation a compact and reliable benchtop flow cytometer equipped + low + with three lasers. The markers selected allow for the Class-switched Adaptive immunity CD45 , SSC , CD19 , memory B cells CD27+, IgD–, CD14– simultaneous identification and analysis of 18 different cell Non-switched Adaptive immunity CD45+, SSClow, CD19+, populations, thus maximizing the amount of information that memory B cells CD27+, IgD+, CD14– can be retrieved from the sample material analyzed. This is Naive B cells Adaptive immunity – CD45+, SSClow, CD19+, critical when input material is limited, as is often the case for non-antigen CD27–, IgD+, CD14– pediatric or disease studies.
    [Show full text]
  • Cd4/Cd8 Panel, Blood
    Lab Dept: Flow and Immunology Test Name: CD4/CD8 PANEL, BLOOD General Information Lab Order Codes: C48P Synonyms: Helper/Suppressor Ratio; T- cells; T-cell subsets; T-cell phenotyping See also: Immune Status Panel and Comprehensive Immune Status Panel CPT Codes: 86359 – T cells, total count 86360 – T cells; absolute CD4 and CD8 count, including ratio Test Includes: CD4(CD3+) and CD8(CD3+) relative percentages, absolute values and a calculated Helper/Suppressor ratio. Logistics Test Indications: This is a minimal antibody panel to monitor immune status. Lab Testing Sections: Flow Cytometry Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: 3 times weekly determined by volume. Transport collected specimen immediately to Flow Cytometry. Routine testing is not available on weekends or holidays. Therefore, specimens cannot be used if drawn the day before a 3 day weekend such as Memorial Day, Labor Day or major holiday that falls on a Monday or Friday. Turnaround Time: 1 – 3 days Special Instructions: See Test Availability Specimen Specimen Type: Whole blood Container: Lavender top (EDTA) tube Draw Volume: 2 mL blood in a 2 mL Lavender (EDTA) tube Minimum volume: 0.5 mL in an EDTA microtainer Collection: Routine venipuncture Special Processing: Keep sample at room temperature and forward promptly to the laboratory. Do not centrifuge, refrigerate, or freeze sample. Patient Preparation: None Sample Rejection: Specimens will not be processed that are clotted; hemolyzed; greater than 72 hours old; collected in the wrong tube type (0.5 mL in a 2 mL tube), or that have been held or handled at a temperature other than room temperature Interpretive Reference Range: Age-dependant reference ranges provided with results.
    [Show full text]
  • Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367
    Medicare Local Coverage Determination Policy Flow Cytometry CPT: 88182, 88184, 88185, 88187, 88188, 88189, 86355, 86356, 86357, 86359, 86360, 86361, 86367 CMS Policy for Alaska, Arizona, Idaho, Montana, North Dakota, Medically Supportive Oregon, South Dakota, Utah, Washington, and Wyoming ICD Codes are listed Local policies are determined by the performing test location. This is determined by the state on subsequent page(s) in which your performing laboratory resides and where your testing is commonly performed. of this document. Coverage Indications, Limitations, and/or Medical Necessity Flow cytometry (FCM) is a complex process to examine blood, body fluids, CSF, bone marrow, lymph node, tonsil, spleen and other solid tissues. The use of peripheral blood and fine needle aspirate material avoids more invasive procedures for diagnosis. A flow cytometer evaluates the physical and/or chemical characteristics of single cells as the cells pass individually in a fluid stream through a measuring device. Surface receptors, intracellular molecules, and DNA bind with fluorescent dyes that allow detection and evaluation. When light of one wave length excites electrons of certain chemicals to energy levels above their ground state and upon return to ground state emits light of a longer wavelength, fluorescence is produced. A flow cytometer detects cell characteristics by measuring the fluorescence produced by fluorochromes conjugated either directly with cell components or conjugated to antibodies directed against cell components. Indications • Cytopenias and Hypercellular Hematolymphoid Disorders Hematolymphoid neoplasia can present with cytopenias (anemia, leucopenia and/or thrombocytopenia) or elevated leukocyte counts. If medical review and preliminary laboratory testing fails to reveal a cause, bone marrow aspiration and biopsy are indicated to rule out an infiltrative process or a stem cell disorder.
    [Show full text]
  • Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature
    cells Article Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature 1, 2, 1, 1, Sónia Fonseca y, Vanessa Pereira y, Catarina Lau z, Maria dos Anjos Teixeira z, Marika Bini-Antunes 3 and Margarida Lima 1,* 1 Laboratory of Cytometry, Unit for Hematology Diagnosis, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001 Porto Porto, Portugal; [email protected] (S.F.); [email protected] (C.L.); [email protected] (M.d.A.T.) 2 Department of Clinical Pathology, Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E), 4434-502 Vila Nova de Gaia, Portugal; [email protected] 3 Laboratory of Immunohematology and Blood Donors Unit, Department of Hematology, Hospital de Santo António (HSA), Centro Hospitalar Universitário do Porto (CHUP), Unidade Multidisciplinar de Investigação Biomédica, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto (UMIB/ICBAS/UP), 4099-001Porto, Portugal; [email protected] * Correspondence: [email protected]; Tel.: + 351-22-20-77-500 These authors contributed equally to this work. y These authors contributed equally to this work. z Received: 10 February 2020; Accepted: 13 March 2020; Published: 16 March 2020 Abstract: Gamma delta T cells (Tc) are divided according to the type of Vδ and Vγ chains they express, with two major γδ Tc subsets being recognized in humans: Vδ2Vγ9 and Vδ1.
    [Show full text]
  • Integrin Activation Controls Regulatory T Cell–Mediated Peripheral Tolerance
    Integrin Activation Controls Regulatory T Cell−Mediated Peripheral Tolerance Jane E. Klann, Stephanie H. Kim, Kelly A. Remedios, Zhaoren He, Patrick J. Metz, Justine Lopez, Tiffani Tysl, This information is current as Jocelyn G. Olvera, Jailal N. Ablack, Joseph M. Cantor, of September 28, 2021. Brigid S. Boland, Gene Yeo, Ye Zheng, Li-Fan Lu, Jack D. Bui, Mark H. Ginsberg, Brian G. Petrich and John T. Chang J Immunol published online 27 April 2018 http://www.jimmunol.org/content/early/2018/04/27/jimmun Downloaded from ol.1800112 Supplementary http://www.jimmunol.org/content/suppl/2018/04/27/jimmunol.180011 Material 2.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 28, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2018 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published April 27, 2018, doi:10.4049/jimmunol.1800112 The Journal of Immunology Integrin Activation Controls Regulatory T Cell–Mediated Peripheral Tolerance Jane E.
    [Show full text]
  • Cross-Presenting Human T Cells Induce Robust CD8 T Cell Responses
    Cross-presenting human ␥␦ T cells induce robust CD8؉ ␣␤ T cell responses Marle` ne Brandesa,1, Katharina Willimanna, Gilles Bioleyb,2, Nicole Le´ vyc, Matthias Eberla,3, Ming Luod, Robert Tampe´ e, Fre´ de´ ric Le´ vyc,4, Pedro Romerob, and Bernhard Mosera,3,5 aInstitute of Cell Biology, University of Bern, CH-3000 Bern 9, Switzerland; bDivision of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, University Hospital (Centre Hospitalier Universitare Vaudois), CH-1005 Lausanne, Switzerland; cLudwig Institute for Cancer Research, Lausanne Branch, CH-1066 Epalinges, Switzerland; dDepartment of Microbiology, University of Alabama, Birmingham, AL 35294; and eInstitute of Biochemistry, Biocenter, Johann Wolfgang Goethe-University, D-60438 Frankfurt am Main, Germany Edited by Peter Cresswell, Yale University School of Medicine, New Haven, CT, and approved December 18, 2008 (received for review October 7, 2008) ␥␦ T cells are implicated in host defense against microbes and receptors and the transformation of these cells into professional tumors but their mode of function remains largely unresolved. APCs, termed ␥␦ T-APCs, capable of inducing CD4ϩ T cell Here, we have investigated the ability of activated human responses (9, 10). Of note, antigen-presenting ␥␦ T cells have also .(V␥9V␦2؉ T cells (termed ␥␦ T-APCs) to cross-present microbial and been reported in cows (11); pigs (12); and, most recently, mice (13 tumor antigens to CD8؉ ␣␤ T cells. Although this process is thought Reactivity to HMB-PP-expressing microbes and certain tumors to be mediated best by DCs, adoptive transfer of ex vivo antigen- suggested to us a role for human ␥␦ T-APCs in the induction of ϩ loaded, human DCs during immunotherapy of cancer patients has pathogen/tumor-specific CD8 T effector cells.
    [Show full text]
  • Complement in Tumourigenesis and the Response to Cancer Therapy
    cancers Review Complement in Tumourigenesis and the Response to Cancer Therapy Rebecca M. O’Brien 1,2, Aoife Cannon 1, John V. Reynolds 1, Joanne Lysaght 1,2 and Niamh Lynam-Lennon 1,* 1 Department of Surgery, Trinity St. James’s Cancer Institute, Trinity Translational Medicine Institute, Trinity College Dublin and St. James’s Hospital, Dublin 8, Ireland; [email protected] (R.M.O.); [email protected] (A.C.); [email protected] (J.V.R.); [email protected] (J.L.) 2 Cancer Immunology and Immunotherapy Group, Trinity St. James’s Cancer Institute, Trinity Translational Medicine Institute, Trinity College Dublin and St. James’s Hospital, Dublin 8, Ireland * Correspondence: [email protected] Simple Summary: Increasing evidence supports a role for complement in the development of cancer and the response to cancer treatments. Dysregulated complement expression within the tumour microenvironment has been linked to the suppression of anti-tumour immunity and poor clinical outcomes. Complement signals have been demonstrated to alter the immune milieu, promote proliferation and facilitate metastasis. Targeting complement signalling in combination with current treatments may have the potential to achieve improved control of tumour growth. Abstract: In recent years, our knowledge of the complement system beyond innate immunity has progressed significantly. A modern understanding is that the complement system has a multifaceted role in malignancy, impacting carcinogenesis, the acquisition of a metastatic phenotype and response to therapies. The ability of local immune cells to produce and respond to complement components has provided valuable insights into their regulation, and the subsequent remodeling of the tumour Citation: O’Brien, R.M.; Cannon, A.; Reynolds, J.V.; Lysaght, J.; microenvironment.
    [Show full text]
  • An Inhibitory Role of the Complement System in T-Cell–Mediated Antitumor Immunity Weiyi Peng , Jodi A
    VIEWS IN THE SPOTLIGHT Complementing T -cell Function: An Inhibitory Role of the Complement System in T-cell–Mediated Antitumor Immunity Weiyi Peng , Jodi A. McKenzie , and Patrick Hwu Summary: New data from Wang and colleagues show that complement C3 suppresses the function of CD8+ tumor-infi ltrating T cells by inhibiting IL10 production, and targeting the complement receptors C3aR and C5aR enhances the antitumor activity of immune checkpoint blockade. Their results not only defi ne a new role of com- plement receptors as T-cell coinhibitory receptors, but also are useful in the development of novel strategies to improve the effectiveness of cancer immunotherapy. Cancer Discov; 6(9); 953–5. ©2016 AACR. See related article by Wang et al., p. 1022 (4). A plethora of cosignaling pathways play a pivotal role in these treatments can lead to durable antitumor immunity in T-cell biology. Although T-cell activation is initiated by the a broad spectrum of cancer types. However, a large portion binding of the T-cell receptor (TCR) and antigenic peptides of patients with cancer still fail to respond to anti-CTLA4 presented by MHC molecules, the amplitude and quality and/or anti–PD-1 therapy. This highlights the importance of T-cell–mediated immune responses are determined by a of studies to better understand the role of T-cell cosignal- balance between costimulatory and coinhibitory signaling ing pathways in the T-cell–mediated antitumor immune pathways. These modulatory signals are transduced into T response and to identify novel T-cell cosignaling receptors. cells mainly through the receptors expressed on the surface Defi ning additional T-cell cosignaling pathways will provide of T cells, which are defi ned as T-cell cosignaling receptors.
    [Show full text]